STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY (MORE THAN 60 YEARS) PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA AFTER 4 CYCLES OF CHOP21-RITUXIMAB (CHOP21-R) THERAPY: